Literature DB >> 19055701

Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.

S R Ostrowski1, T L Katzenstein, B K Pedersen, J Gerstoft, H Ullum.   

Abstract

Despite undetectable viral load in conventional assays, probably all human immunodeficiency virus (HIV)-1 infected patients have residual viraemia (RV) detectable by ultra-sensitive assays. To study this issue, this study investigated virologic and immunologic consequences of RV in highly active antiretroviral therapy (HAART)-treated HIV-1-infected patients with plasma HIV-1 RNA <or=20 copies/ml. The study included 32 HAART-treated HIV-1-infected patients with HIV-1 RNA <or=20 copies/ml followed prospectively 6-monthly for 24 months. RV was detected by transcription-mediated amplification (TMA-RV) technique (Procleix HIV-1 Discriminatory Assay; Chiron) and by PCR (PCR-RV, Amplicor HIV-1 Monitor Assay; Roche Diagnostics). The association between RV and proviral-HIV-1-DNA, CD4-count, CD8-count, soluble [soluble tumour necrosis factor receptor (TNFr)-II, beta(2)-microglobulin, immunoglobulins] and cellular (HLA-DR, CD38, CD45RO, CD45RA, CD62L) T-cell markers of immune activation was investigated. In the 24-months study-period, 23 patients had >or=1 episode with TMA-RV whereas 9 patients had undetectable TMA-RV throughout the study-period. Time-points with TMA-RV and PCR-RV were associated with higher circulating sTNFrII (+0.234 ng/ml, P = 0.030) and beta(2)-microglobulin (+22 nmol/l, P = 0.016) and time-points with PCR-RV were also associated with higher IgA (+0.82 micromol/l, P = 0.035) and CD8-count (+1.18-fold, P = 0.001). Patients with TMA-RV in the study-period had higher HIV-1 RNA pre-HAART (P = 0.032). RV was not associated with proviral-HIV-1-DNA, CD4-count, CD4+HLA-DR+, CD8+HLA-DR+CD38+, CD4+CD45RA-CD45RO+, CD8+CD45RA-CD45RO+, CD4+CD45RA+CD62L+, CD8+CD45RA+CD62L+ T cells, IgG or IgM. In conclusion, RV was associated with increased blood levels of soluble immune activation markers in HAART-treated HIV-1-infected patients. The finding that RV was associated with higher pre-HAART plasma viral load suggests that RV is linked to pre-HAART disease progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19055701     DOI: 10.1111/j.1365-3083.2008.02184.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  34 in total

1.  Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.

Authors:  Jesper F Højen; Thomas A Rasmussen; Karen Lise D Andersen; Anni A Winckelmann; Rune R Laursen; Jesper D Gunst; Holger J Møller; Mayumi Fujita; Lars Østergaard; Ole S Søgaard; Charles A Dinarello; Martin Tolstrup
Journal:  Mol Med       Date:  2015-04-14       Impact factor: 6.354

2.  Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Authors:  Emily C Liang; Lindsay Sceats; Nicholas L Bayless; Dara M Strauss-Albee; Jessica Kubo; Philip M Grant; David Furman; Manisha Desai; David A Katzenstein; Mark M Davis; Andrew R Zolopa; Catherine A Blish
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

Review 3.  Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.

Authors:  Denise C Hsu; Irini Sereti
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 4.  Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages.

Authors:  Davide Gibellini; Alberto Clò; Silvia Morini; Anna Miserocchi; Cristina Ponti; Maria Carla Re
Journal:  World J Virol       Date:  2013-05-12

5.  Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study.

Authors:  Elie Helou; Sheela Shenoi; Tassos Kyriakides; Marie-Louise Landry; Michael Kozal; Lydia Aoun Barakat
Journal:  J Int Assoc Provid AIDS Care       Date:  2016-11-30

6.  Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.

Authors:  Steven A Yukl; Peilin Li; Katsuya Fujimoto; Harry Lampiris; Chuanyi M Lu; C Bradley Hare; Steven G Deeks; Teri Liegler; Mark Pandori; Diane V Havlir; Joseph K Wong
Journal:  J Virol Methods       Date:  2011-04-22       Impact factor: 2.014

7.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Authors:  Saverio G Parisi; Samantha Andreis; Monica Basso; Silvia Cavinato; Renzo Scaggiante; Marzia Franzetti; Massimo Andreoni; Giorgio Palù; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2017-09-01       Impact factor: 3.402

8.  Persistent immune activation in chronic HIV infection: do any interventions work?

Authors:  Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

Review 9.  The macrophage: the intersection between HIV infection and atherosclerosis.

Authors:  Suzanne M Crowe; Clare L V Westhorpe; Nigora Mukhamedova; Anthony Jaworowski; Dmitri Sviridov; Michael Bukrinsky
Journal:  J Leukoc Biol       Date:  2009-12-01       Impact factor: 4.962

10.  HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

Authors:  Maud Mavigner; Pierre Delobel; Michelle Cazabat; Martine Dubois; Fatima-Ezzahra L'faqihi-Olive; Stéphanie Raymond; Christophe Pasquier; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.